Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 29-Sep 1:53 PM ET)
ACT NOW - The M&A Class Action Firm Is Investigating the Merger -- FHB, INDV, ITGR, and LNTH
PRNewswire (Mon, 28-Sep 7:22 PM ET)
Business Wire (Thu, 24-Sep 5:16 PM ET)
Indivior Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing
Market Chameleon (Thu, 17-Sep 3:32 AM ET)
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Globe Newswire (Thu, 17-Sep 7:00 AM ET)
Globe Newswire (Tue, 8-Sep 10:45 AM ET)
Business Wire (Sat, 29-Aug 7:27 AM ET)
Globe Newswire (Mon, 3-Aug 5:07 PM ET)
PRNewswire (Mon, 3-Aug 3:15 PM ET)
Indivior Delivers Record Q2 Results With 111% EBITDA Growth and Raises Full-Year Outlook
Market Chameleon (Mon, 3-Aug 3:54 AM ET)
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Indivior Pharmaceuticals trades on the NASDAQ stock market under the symbol INDV.
As of September 30, 2026, INDV stock price declined to $36.10 with 510,761 million shares trading.
INDV has a beta of 0.24, meaning it tends to be less sensitive to market movements. INDV has a correlation of 0.01 to the broad based SPY ETF.
INDV has a market cap of $4.26 billion. This is considered a Mid Cap stock.
Last quarter Indivior Pharmaceuticals reported $343 million in Revenue and $1.15 earnings per share. This beat revenue expectation by $36 million and exceeded earnings estimates by $.23.
In the last 3 years, INDV traded as high as $42.81 and as low as $7.33.
The top ETF exchange traded funds that INDV belongs to (by Net Assets): IJR, VTI, IWM, VB, VBK.
INDV has outperformed the market in the last year with a price return of +49.8% while the SPY ETF gained +16.7%. However, in the short term, INDV had mixed performance relative to the market. It has underperformed in the last 3 months, returning -12.5% vs +3.7% return in SPY. But in the last 2 weeks, INDV shares have fared better than the market returning +5.5% compared to SPY +1.5%.
INDV support price is $35.94 and resistance is $37.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INDV shares will trade within this expected range on the day.
